Shire plc (SHPG) Analysts See $3.89 EPS

February 14, 2018 - By Adrian Erickson

 Shire plc (SHPG) Analysts See $3.89 EPS

Analysts expect Shire plc (NASDAQ:SHPG) to report $3.89 EPS on February, 15.They anticipate $0.52 EPS change or 15.43 % from last quarter’s $3.37 EPS. SHPG’s profit would be $1.10 billion giving it 8.53 P/E if the $3.89 EPS is correct. After having $3.81 EPS previously, Shire plc’s analysts see 2.10 % EPS growth. The stock increased 0.30% or $0.4 during the last trading session, reaching $132.67. About 1.19M shares traded. Shire plc (NASDAQ:SHPG) has risen 4.69% since February 14, 2017 and is uptrending. It has underperformed by 12.01% the S&P500.

Shire plc (NASDAQ:SHPG) Ratings Coverage

Among 25 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 20 have Buy rating, 0 Sell and 5 Hold. Therefore 80% are positive. Shire plc (ADR) had 65 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was upgraded by HSBC to “Hold” on Wednesday, September 30. The stock has “Buy” rating by Liberum Capital on Tuesday, November 14. The rating was reinitiated by Morgan Stanley with “Overweight” on Friday, June 3. The rating was upgraded by Bank of America to “Buy” on Monday, January 18. The firm has “Buy” rating by Jefferies given on Wednesday, December 20. On Thursday, May 26 the stock rating was initiated by Stifel Nicolaus with “Buy”. The stock of Shire plc (NASDAQ:SHPG) earned “Buy” rating by SunTrust on Thursday, October 26. The rating was maintained by RBC Capital Markets on Monday, July 10 with “Buy”. The firm has “Hold” rating given on Monday, September 26 by HSBC. The stock has “Buy” rating by HSBC on Tuesday, November 3.

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company has market cap of $37.64 billion. The firm offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. It has a 25.07 P/E ratio. The Company’s marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease.

Another recent and important Shire plc (NASDAQ:SHPG) news was published by Benzinga.com which published an article titled: “Earnings Scheduled For February 14, 2018” on February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.